SCHEDULE: Sofinnova Increases Stake in Abivax SA, Acquiring $17.3M in Public Offering

Sofinnova Crossover I SLP and its affiliates have increased their beneficial ownership in Abivax SA to 11.4% of voting rights through a $17.28 million acquisition of American Depositary Shares in a recent public offering.

Summary

• Sofinnova Crossover I SLP (SC) and its affiliates, including Sofinnova Partners SAS and members of SC's investment committee, have updated their beneficial ownership in Abivax SA.
• On July 23, 2025, SC purchased 270,000 American Depositary Shares (ADSs) of Abivax SA at a price of $64 per share, totaling an aggregate purchase price of $17,280,000.
• The purchase was part of Abivax SA's underwritten public offering, which closed on July 28, 2025, and resulted in the issuance of 11,679,400 ADSs after the full exercise of the over-allotment option.
• As of July 28, 2025, SC directly holds 5,534,739 Ordinary Shares, representing approximately 7.4% of Abivax SA's outstanding Ordinary Shares (based on 75,151,333 shares outstanding).
• The reporting persons collectively hold 9,599,478 voting rights, which represents approximately 11.4% of Abivax SA's outstanding voting rights (based on 84,464,060 voting rights outstanding).
• The funds for the acquisition came from working capital.

Sentiment

Score: 7

Explanation: The filing details a significant investment by Sofinnova in Abivax SA through a public offering, which is generally a positive signal for the issuer as it provides capital and demonstrates investor confidence.

Positives

• Sofinnova Crossover I SLP's participation in Abivax SA's public offering demonstrates continued investment and confidence in the company.
• The acquisition of 270,000 ADSs for $17,280,000 provides capital to Abivax SA.

Future Outlook

The reporting persons acquired the shares for investment purposes and retain the right to change their investment intent, acquire additional securities, or dispose of existing holdings. They may also consider and discuss matters with Abivax SA's management or board, and may formulate plans with respect to such matters.

Industry Context

This filing indicates a significant investment by a venture capital firm (Sofinnova) in a biotechnology or pharmaceutical company (Abivax SA), which is common in the life sciences sector where companies often rely on public offerings and institutional investments for funding drug development and operations.

Stakeholder Impact

• Shareholders: Increased institutional ownership and potential for future influence by Sofinnova; dilution from the public offering.
• Abivax SA: Received capital from the public offering, including Sofinnova's investment, which can support operations and strategic initiatives.

Next Steps

• Reporting Persons may acquire additional Ordinary Shares or other securities of Abivax SA.
• Reporting Persons may sell or otherwise dispose of all or part of their beneficially owned Ordinary Shares or other securities.
• Reporting Persons may engage in ordinary course transactions with financial institutions regarding the securities.
• Reporting Persons may consider and formulate plans regarding matters described in Items 4(a)-(j) of Schedule 13D instructions, and may hold discussions or make formal proposals to Abivax SA management or board.

Key Dates

Keywords

Abivax SA, Sofinnova, Schedule 13D, beneficial ownership, public offering, ADSs, ordinary shares, investment, voting rights, capital raise